Lipidomics is a measurement of a large scale of lipid species to understand roles of their carbon atoms, dual bonds, or isomerism in the lipid molecule. Clinical lipidomics was recently defined “as a new integrative biomedicine to discover the correlation and regulation between a large scale of lipid elements measured and analyzed in liquid biopsies from patients with those patient phenomes and clinical phenotypes”. The first step to translate lipidomics into clinical lipidomics is to settle a number of standard operation procedures and protocols of lipidomics performance and measurement. Clinical lipidomics is the part of clinical trans‐omics which was coined as a new emerging scientific discipline where clinical phenomes are integrated with molecular multiomics. We believe it is the time to translate lipid science and lipidomics into clinical application and to understand the importance of clinical lipidomics as one of the most helpful approaches during the design and decision‐making of therapeutic strategies for individuals. We emphasize here that clinical lipidomics should be merged with clinical phenomes, e.g. patient signs and symptoms, biomedical analyses, pathology, images, and responses to therapies, although it is difficult to integrate and fuse the information of clinical lipidomics with clinical phenomes. It will be a great achievement if we can draw the networks of lipidomic species fused with networks of genes and proteins to describe the molecular mechanisms of the disease in multi‐dimensions.
In order to overcome the formidable challenges posed by the intricate physiological barriers of the brain, the employment of intranasal administration (INA) has emerged as an unconventional method for drug delivery, offering distinct advantages such as non‐invasiveness and enhanced pharmacokinetic characteristics within the brain. Primarily exploiting the distinct conduit offered by the olfactory and/or trigeminal nerve systems, the INA route effectively delivers therapeutic agents. With introducing appropriate improvements to the drug formulation, such as the incorporation of nanocarriers, the efficacious delivery via the INA approach has gained considerable traction for the treatment of neurological disorders. This concise review highlights the notable progress in INA delivery and explores the potential therapeutic modalities inherent in this promising paradigm.
Pulmonary fibrosis (PF) is a common pathological feature of acute and chronic inflammatory lung diseases that currently has no effective clinical treatment. Mesenchymal stem cells (MSCs) are considered to be an ideal cell source for regenerating injured tissues, as they are easily extracted and expanded, have a limited risk of tumorigenicity, and lack immunogenicity. Recently, MSC-based therapies have been suggested as potential therapeutic strategies for attenuating PF. Although the administration of MSCs has been reported to have anti-inflammatory and anti-fibrotic effects in PF, further studies are required to optimize the MSC source and dose, delivery time, and route of administration to improve their protective effects. Moreover, the mechanisms underlying MSC-based therapies for PF remain elusive. Here, we review recently published data on MSC administration for the treatment of PF to provide insights into the therapeutic impact of MSC delivery procedures and sources. In addition, we discuss the potential mechanisms underlying the effects of MSC administration on PF and highlight promising strategies for improving the beneficial effects of MSCs.
20 May 2022 in Clinical and Translational Medicine